- Home
- FINW vs CRVS Comparison
FINW vs CRVS Comparison
Compare FINW & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FINW | CRVS |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.2M | 634.0M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FINW | CRVS |
|---|---|---|
| Price | $17.96 | $7.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $22.00 | $13.75 |
| AVG Volume (30 Days) | 22.4K | ★ 1.6M |
| Earning Date | 01-29-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $80,198,000.00 | N/A |
| Revenue This Year | $83.64 | N/A |
| Revenue Next Year | $38.08 | N/A |
| P/E Ratio | $16.92 | ★ N/A |
| Revenue Growth | ★ 14.76 | N/A |
| 52 Week Low | $13.49 | $2.54 |
| 52 Week High | $22.49 | $9.60 |
Technical Indicators
Market Signals| Indicator | FINW | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 39.40 |
| Support Level | $17.79 | $7.34 |
| Resistance Level | $18.66 | $8.00 |
| Average True Range (ATR) | 0.57 | 0.50 |
| MACD | 0.03 | -0.13 |
| Stochastic Oscillator | 53.86 | 7.40 |
Price Performance
Historical ComparisonAbout FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).